Alkermes plc
ALKS
Clasificación en acciones
#2720
Alkermes plc, a biopharmaceutical company, engages in the research,... Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Precio por acción
$41.70
Capitalización bursátil
$7.00B
Cambio (1 día)
1.16%
Cambio (1 año)
37.81%
País
IE
Comercio Alkermes plc (ALKS)
Categoría
Healthcare
Ganancias de Alkermes plc (ALKS)
Ganancias en Jun 2026 TTM: $97.32M
Secondo gli ultimi rapporti finanziari di Alkermes plc, gli utili attuali della società sono $97.32M. Nel 2023, la società ha registrato un utile di $421.52M, un aumento con respecto a agli utili del 2022, che erano di $-31.13M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Alkermes plc desde 2000 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $97.32M | -78.07% |
| 2024 | $443.75M | 5.27% |
| 2023 | $421.52M | -1,454.15% |
| 2022 | $-31.13M | -135.48% |
| 2021 | $87.73M | -190.87% |
| 2020 | $-96.54M | -51.01% |
| 2019 | $-197.06M | 55.20% |
| 2018 | $-126.97M | -11.38% |
| 2017 | $-143.27M | -33.17% |
| 2016 | $-214.39M | -4.29% |
| 2015 | $-224.01M | 1,496.73% |
| 2014 | $-14.03M | -139.58% |
| 2013 | $35.44M | 0.00% |
| 2012 | $35.44M | -130.98% |
| 2011 | $-114.39M | 146.05% |
| 2010 | $-46.49M | 4.00% |
| 2009 | $-44.70M | -134.12% |
| 2008 | $131.01M | -24.20% |
| 2007 | $172.83M | 1,539.29% |
| 2006 | $10.54M | 0.00% |
| 2005 | 0.00 | -100.00% |
| 2004 | $-75.17M | 0.00% |
| 2003 | 0.00 | -100.00% |
| 2002 | $-106.90M | 74.23% |
| 2001 | $-61.35M | 263.71% |
| 2000 | $-16.87M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | 5,320.16% |
US
|
|
| $-3.09B | -3,272.01% |
US
|
|
| $-4.02B | -4,226.79% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 1,904.37% |
NL
|
